A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study

Clinical Site 128, New York

Clinical Site 102, Staten Island

Clinical Site 106, Media

Clinical Site 118, Philadelphia

Clinical Site 136, Rockville

Clinical Site 131, Baltimore

Clinical Site 143, Raleigh

Clinical Site 111, Hickory

Clinical Site 104, Decatur

Clinical Site 122, Marietta

Clinical Site 140, Atlanta

Clinical Site 105, Orlando

Clinical Site 137, Orlando

Clinical Site 108, Miami Gardens

Clinical Site 107, Hialeah

Clinical Site 116, Miami

Clinical Site 138, Middleburg Heights

Clinical Site 127, North Canton

Clinical Site 151, Dearborn Heights

Clinical Site 139, St Louis

Clinical Site 125, Lincoln

Clinical Site 120, Little Rock

Clinical Site 129, Little Rock

Clinical Site 126, Bentonville

Clinical Site 144, Plano

Clinical Site 114, Fort Worth

Clinical Site 109, Houston

Clinical Site 145, Denver

Clinical Site 147, Draper

Clinical Site 149, Missouri City

Clinical Site 110, Las Vegas

Clinical Site 112, Torrance

Clinical Site 115, Bellflower

Clinical Site 113, Oceanside

Clinical Site 123, Riverside

Clinical Site 124, Santa Ana

Clinical Site 141, Anaheim

Clinical Site 132, Lafayette

Clinical Site 117, Oakland

Clinical Site 142, Santa Rosa

Clinical Site 135, Bellevue

Clinical Site 103, Boston

Clinical Site 121, Boston

Clinical Site 101, Marlton

Clinical Site 148, Toms River

Clinical Site 150, San Juan